December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corvus Pharmaceuticals, Inc. - Common Stock (NQ:CRVS)

14.01 -0.03 (-0.21%)
Streaming Delayed Price Updated: 11:41 AM EDT, Sep 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 79,338
Open 13.86
Bid (Size) 13.99 (200)
Ask (Size) 14.04 (300)
Prev. Close 14.04
Today's Range 13.84 - 14.17
52wk Range 5.580 - 26.95
Shares Outstanding 74,681,872
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Corvus Pharmaceuticals (CRVS) Q2 2026 Earnings Call Transcript ↗
Soquelitinib advances across multiple indications, with cash runway extended into 2028. 
Via The Motley Fool
Topics Earnings
News headline image
Corvus Pharmaceuticals Q2 Earnings Call Highlights ↗
Corvus Pharmaceuticals (NASDAQ:CRVS) reported a wider second-quarter loss as it increased spending on clinical development of soquelitinib, its selective ITK inhibitor, while outlining expected... 
Via MarketBeat
Topics Earnings

Performance

YTD
+91.4%
+91.4%
1 Month
+4.8%
+4.8%
3 Month
+16.0%
+16.0%
6 Month
-21.7%
-21.7%
1 Year
+147.1%
+147.1%

More News

Read More
Corvus Pharmaceuticals (NASDAQ:CRVS) Misses Q2 Loss Estimates as Clinical-Stage Spending Continues ↗
Via Chartmill
News headline image
Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy? ↗
Via The Motley Fool
Topics Regulatory Compliance
Corvus Pharmaceuticals Reports Q1 2026 Results; Atopic Dermatitis Program Takes Center Stage (NASDAQ:CRVS) ↗
Via Chartmill
Corvus Pharmaceuticals (NASDAQ:CRVS) Reports Q4 Earnings Miss Amid Positive Pipeline Data ↗
Via Chartmill
Topics Earnings
Why Is CRVS Stock Rising Today? ↗
Via Stocktwits
News headline image
Adams Street Partners Exits Its 223,000-Share Paymentus (PAY) Position for $5.9 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Corvus (CRVS) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Earnings Scheduled For November 4, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
Via Benzinga
News headline image
Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026 ↗
Via MarketBeat
News headline image
CRVS Stock Surges Pre-Market After Corvus Expands Equity Raise To $175 Million ↗
Via Stocktwits
Dow, Nasdaq, S&P 500 Futures Tick Higher After Wall Street’s Worst Day In 3 Months: Why NFLX, AAPL, CRVS, GME, UAL Are In Focus Today ↗
Via Stocktwits
Topics Stocks
News headline image
Corvus Pharma Stock Dips Over 6% After-Hours Following Best Day Ever — What Went Wrong? ↗
Via Stocktwits
News headline image
Stock Market Today, Jan. 20: Corvus Pharmaceuticals Surges After Positive Phase 1 Eczema Drug Data ↗
Via The Motley Fool
Topics Stocks
Here are the top movers in Tuesday's session. ↗
Via Chartmill
Tuesday's session: top gainers and losers ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Corvus Pharmaceuticals Inc (NASDAQ:CRVS) Reports Narrower-Than-Expected Q2 2025 Loss, Shares Rise on Clinical Progress ↗
Via Chartmill
News headline image
Corvus (CRVS) Q2 Loss Beats Estimates ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Via Benzinga
News headline image
Corvus Gets Price Target Hike From Oppenheimer On Positive Drug Trial Results: Retail’s Pleased ↗
Via Stocktwits

Frequently Asked Questions

Is Corvus Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Corvus Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Corvus Pharmaceuticals, Inc. - Common Stock trade on?
Corvus Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Corvus Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Corvus Pharmaceuticals, Inc. - Common Stock is CRVS on the Nasdaq Stock Market
What is the current price of Corvus Pharmaceuticals, Inc. - Common Stock?
The current price of Corvus Pharmaceuticals, Inc. - Common Stock is 14.01
When was Corvus Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Corvus Pharmaceuticals, Inc. - Common Stock was at 09/01/26 11:41 AM ET
What is the market capitalization of Corvus Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Corvus Pharmaceuticals, Inc. - Common Stock is 1.05B
How many shares of Corvus Pharmaceuticals, Inc. - Common Stock are outstanding?
Corvus Pharmaceuticals, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.